Factors at admission associated with bleeding risk in medical patients: Findings from the improve investigators

Chest

Volumn 139, Issue 1, 2011, Pages 69-79

  Decousus, Hervé ^a   Tapson, Victor F ^c   Bergmann, Jean François ^b   Chong, Beng H ^d   Froehlich, James B ^e   Kakkar, Ajay K ^f   Merli, Geno J ^g   Monreal, Manuel ^h   Nakamura, Mashio ⁱ   Pavanello, Ricardo ^j   Pini, Mario ^k   Piovella, Franco ^l   Spencer, Frederick A ^m   Spyropoulos, Alex C ^m   Turpie, Alexander G G ^m   Zotz, Rainer B ⁿ   FitzGerald, Gordon ^o   Anderson, Frederick A ^o  

^a HÔPITAL NORD   (France)

^b HÔPITAL LARIBOISIÈRE   (France)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^f QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^g THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

^h HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

ⁱ MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j Hospital do Coracao Clinica Medica São Paulo   (Brazil)

^k Fidenza Hospital   (Italy)

^l FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^m HAMILTON HEALTH SCIENCES   (Canada)

ⁿ Hämostase Institut Düsseldorf   (Germany)

^o UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADULT; AGED; AGING; ARTICLE; BLEEDING TENDENCY; BRAIN HEMORRHAGE; CENTRAL VENOUS CATHETER; COMPRESSION GARMENT; FEMALE; GASTRODUODENAL ULCER; GASTROINTESTINAL HEMORRHAGE; HEMATOMA; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; INTENSIVE CARE UNIT; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; KAPLAN MEIER METHOD; KIDNEY FAILURE; LENGTH OF STAY; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MULTIPLE REGRESSION; NEOPLASM; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RHEUMATIC DISEASE; RISK FACTOR; SEX DIFFERENCE; THROMBOCYTE COUNT; VENOUS THROMBOEMBOLISM;

EID: 78651416799     PISSN: 00123692     EISSN: 19313543     Source Type: Journal    
DOI: 10.1378/chest.09-3081     Document Type: Article

References (39)

1. Cohen AT, Agnelli G, Anderson FA, et al; VTE Impact Assessment Group in Europe (VITAE). Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98(4):756-764.
2. Tapson VF, Hyers TM, Waldo AL, et al; NABOR (National Anticoagulation Benchmark and Outcomes Report) Steering Committee. Antithrombotic therapy practices in US hospitals in an era of practice guidelines. Arch Intern Med. 2005;165(13):1458-1464.
3. Sandler DA, Martin JF. Autopsy proven pulmonary embolism in hospital patients: are we detecting enough deep vein thrombosis? J R Soc Med. 1989;82(4):203-205.
4. Anderson FA Jr, Wheeler HB, Goldberg RJ, et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med. 1991;151(5):933-938.
5. Baglin TP, White K, Charles A. Fatal pulmonary embolism in hospitalised medical patients. J Clin Pathol. 1997;50(7):609-610.
6. Anderson FA Jr, Zayaruzny M, Heit JA, Fidan D, Cohen AT. Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol. 2007;82(9):777-782. (Pubitemid 350194504)
7. Cohen AT, Tapson VF, Bergmann JF, et al; ENDORSE Investigators. Venous thromboembolism risk and prophylaxis in the acute hospital care setting (ENDORSE study): a multinational cross-sectional study. Lancet. 2008;371(9610):387-394.
8. Douketis JD. Prevention of venous thromboembolism in hospitalized medical patients: addressing some practical questions. Curr Opin Pulm Med. 2008;14(5):381-388.
9. Samama MM, Cohen AT, Darmon JY, et al; Prophylaxis in Medical Patients with Enoxaparin Study Group. A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med. 1999;341(11):793-800.
10. Leizorovicz A, Cohen AT, Turpie AG, Olsson CG, Vaitkus PT, Goldhaber SZ; PREVENT Medical Thromboprophylaxis Study Group. Randomized, placebo-controlled trial of dalteparin for the prevention of venous thromboembolism in acutely ill medical patients. Circulation. 2004;110(7):874-879. (Pubitemid 39096017)
11. Cohen AT, Davidson BL, Gallus AS, et al; ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006;332(7537):325-329.
12. Dentali F, Douketis JD, Gianni M, Lim W, Crowther MA. Meta-analysis: anticoagulant prophylaxis to prevent symptomatic venous thromboembolism in hospitalized medical patients. Ann Intern Med. 2007;146(4):278-288. (Pubitemid 351650614)
13. Lloyd NS, Douketis JD, Moinuddin I, Lim W, Crowther MA. Anticoagulant prophylaxis to prevent asymptomatic deep vein thrombosis in hospitalized medical patients: a systematic review and meta-analysis. J Thromb Haemost. 2008;6(3):405-414.
14. Geerts WH, Bergqvist D, Pineo GF, et al; American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians evidence-based clinical practice guidelines (8th edition). Chest. 2008;133(6 Suppl):381S-453S.
15. Ageno W, Squizzato A, Ambrosini F, et al. Thrombosis prophylaxis in medical patients: a retrospective review of clinical practice patterns. Haematologica. 2002;87(7):746-750.
16. Goldhaber SZ, Tapson VF; DVT FREE Steering Committee. A prospective registry of 5,451 patients with ultrasound-confirmed deep vein thrombosis. Am J Cardiol. 2004;93(2):259-262.
17. Kahn SR, Panju A, Geerts W, et al; CURVE study investigators. Multicenter evaluation of the use of venous thromboembolism prophylaxis in acutely ill medical patients in Canada. Thromb Res. 2007;119(2):145-155.
18. Tapson VF, Decousus H, Pini M, et al; for the IMPROVE Investigators. Venous thromboembolism prophylaxis in acutely ill hospitalized medical patients: findings from the International Medical Prevention Registry on Venous Thromboembolism. Chest. 2007;132(3):936-945.
19. Kamphuisen PW, Agnelli G, Sebastianelli M. Prevention of venous thromboembolism after acute ischemic stroke. J Thromb Haemost. 2005;3(6):1187-1194.
20. Laporte S, Mismetti P, Decousus H, et al; RIETE Investigators. Clinical predictors for fatal pulmonary embolism in 15,520 patients with venous thromboembolism: findings from the Registro Informatizado de la Enfermedad Trombo-Embolica venosa (RIETE) Registry. Circulation. 2008;117(13):1711-1716.
21. Ruíz-Giménez N, Suárez C, González R, et al; RIETE Investigators. Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost. 2008;100(1):26-31.
22. Cohen AT, Alikhan R, Arcelus JI, et al. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost. 2005;94(4):750-759.
23. Kucher N, Koo S, Quiroz R, et al. Electronic alerts to prevent venous thromboembolism among hospitalized patients. N Engl J Med. 2005;352(10):969-977.
24. Büller HR, Davidson BL, Decousus H, et al; Matisse Investigators. Subcutaneous fondaparinux versus intravenous unfractionated heparin in the initial treatment of pulmonary embolism. N Engl J Med. 2003;349(18):1695-1702.
25. Büller HR, Davidson BL, Decousus H, et al; Matisse Investigators. Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: a randomized trial. Ann Intern Med. 2004;140(11):867-873.
26. Buller HR, Cohen AT, Davidson B, et al; van Gogh Investigators. Idraparinux versus standard therapy for venous thromboembolic disease. N Engl J Med. 2007;357(11):1094-1104.
27. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3(4):692-694.
28. Schulman S, Beyth RJ, Kearon C, Levine MN; American College of Chest Physicians. Hemorrhagic complications of anticoagulant and thrombolytic treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 S uppl):257S-298S.
29. Levine MN, Hirsh J, Kelton JG. Heparin-induced bleeding. In: Lane DA, Lindahl U, eds. Heparin: Chemical and Biological Properties Clinical Applications. London, England : Edward Arnold; 1989:517-532.
30. Campbell NR, Hull RD, Brant R, Hogan DB, Pineo GF, Raskob GE. Aging and heparin-related bleeding. Arch Intern Med. 1996;156(8):857-860.
31. Lacut K, Bressollette L, Le Gal G, et al; VICTORIAh (Venous Intermittent Compression and Thrombosis Occurrence Related to Intra-cerebral Acute hemorrhage) Investigators. Prevention of venous thrombosis in patients with acute intracerebral hemorrhage. Neurology. 2005;65(6):865-869.
32. Dennis M, Sandercock PA, Reid J, et al; CLOTS Trials Collaboration. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial 1): a multicentre, randomised controlled trial. Lancet. 2009;373(9679):1958-1965.
33. Goldhaber SZ. Newly diagnosed venous thromboembolism: which patients will bleed after anticoagulation is initiated? Thromb Haemost. 2008;100(1):5-6.
34. Poli D, Antonucci E, Grifoni E, Abbate R, Gensini GF, Prisco D. Bleeding risk during oral anticoagulation in atrial fibrillation patients older than 80 years. J Am Coll Cardiol. 2009;54(11):999-1002.
35. Singer DE, Chang Y, Fang MC, et al. The net clinical benefit of warfarin anticoagulation in atrial fibrillation. Ann Intern Med. 2009;151(5):297-305.
36. Palareti G, Cosmi B. Bleeding with anticoagulation therapy - who is at risk, and how best to identify such patients. Thromb Haemost. 2009;102(2):268-278.
37. Fox KAA, Dabbous OH, Goldberg RJ, et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ. 2006;333(7578):1091-1094.
38. Mehta SR, Granger CB, Boden WE, et al; TIMACS Investiga tors. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med. 2009;360(21):2165-2175.
39. Bassand JP, Hamm CW, Ardissino D, et al; Task Force for Diagnosis and Treatment of Non-ST-Segment Elevation Acute Coronary Syndromes of European Society of Cardiology. Guidelines for the diagnosis and treatment of non-ST-segment elevation acute coronary syndromes. Eur Heart J. 2007;28(13):1598-1660.